Healthcare firm Sun Pharmaceutical Industries gained 1 percent on Wednesday after the foreign research house CLSA upgraded the stock to a `buy' with a target price of Rs 990 a share.
CLSA expects a strong ramp up in its US business led by expansion in the recently acquired URL Generics.
Caraco Pharma, a subsidiary of Sun Pharmaceutical, acquired Japanese drug maker Takeda Pharmaceuticals' US-based generics subsidiary URL Pharma in December.
This was Sun Pharma's second acquisition in the United States within two months after it decided to buy skin treatment firm Dusa Pharmaceuticals Inc for USD 230 million.
At 11:24 hours IST, shares went up 0.97 percent to Rs 835.40 on Bombay Stock Exchange.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
